# Paolo M Comoglio

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 291 papers | 30,252 citations | 3731 89 h-index | 5120 166 g-index |
| 294 all docs | 294 docs citations | 294 times ranked | 25360 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of â€˜MET-addictedâ€™ cancers. Journal of Experimental and Clinical Cancer Research, 2022, 41, 112. | 8.6 | 5 |
| 2 | METâˆ†14 promotes a ligand-dependent, AKT-driven invasive growth. Life Science Alliance, 2022, 5, e202201409. | 2.8 | 7 |
| 3 | MET Exon 14 Skipping: A Case Study for the Detection of Genetic Variants in Cancer Driver Genes by Deep Learning. International Journal of Molecular Sciences, 2021, 22, 4217. | 4.1 | 6 |
| 4 | Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. Nature Communications, 2021, 12, 2498. | 12.8 | 20 |
| 5 | Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptorâ€dependent mechanisms. Journal of Thrombosis and Haemostasis, 2021, 19, 2235-2247. | 3.8 | 2 |
| 6 | HGF and MET: From Brain Development to Neurological Disorders. Frontiers in Cell and Developmental Biology, 2021, 9, 683609. | 3.7 | 47 |
| 7 | ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell Reports, 2021, 36, 109455. | 6.4 | 18 |
| 8 | A receptor-antibody hybrid hampering MET-driven metastatic spread. Journal of Experimental and Clinical Cancer Research, 2021, 40, 32. | 8.6 | 6 |
| 9 | Cancer of Unknown Primary ( <scp>CUP</scp> ): genetic evidence for a novel nosological entity? A case report. EMBO Molecular Medicine, 2020, 12, e11756. | 6.9 | 10 |
| 10 | ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy. International Journal of Molecular Sciences, 2019, 20, 2164. | 4.1 | 168 |
| 11 | Met inhibition revokes IFNÎ³-induction of PD-1 ligands in MET-amplified tumours. British Journal of Cancer, 2019, 120, 527-536. | 6.4 | 34 |
| 12 | Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nature Reviews Cancer, 2018, 18, 341-358. | 28.4 | 248 |
| 13 | Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibodyâ€â€œdecoyâ€• strategy. International Journal of Cancer, 2018, 143, 1774-1785. | 5.1 | 11 |
| 14 | A Molecularly Annotated Model of Patient-Derived Colon Cancer Stemâ€"Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. Clinical Cancer Research, 2018, 24, 807-820. | 7.0 | 23 |
| 15 | Whole exome sequencing identifies a germline <i>MET</i> mutation in two siblings with hereditary wild-type <i>RET</i> medullary thyroid cancer. Human Mutation, 2018, 39, 371-377. | 2.5 | 24 |
| 16 | MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. International Journal of Molecular Sciences, 2018, 19, 3920. | 4.1 | 24 |
| 17 | Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10058-10063. | 7.1 | 17 |
| 18 | The expression of LINE1â€<i>MET</i> chimeric transcript identifies a subgroup of aggressive breast cancers. International Journal of Cancer, 2018, 143, 2838-2848. | 5.1 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin. EBioMedicine, 2017, 24, 34-42. | 6.1 | 8 |
| 20 | Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. Stem Cells, 2017, 35, 2218-2228. | 3.2 | 47 |
| 21 | Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. Oncogene, 2017, 36, 1200-1210. | 5.9 | 28 |
| 22 | Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. Oncotarget, 2017, 8, 38193-38213. | 1.8 | 22 |
| 23 | Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody. Cancer Research, 2016, 76, 5019-5029. | 0.9 | 21 |
| 24 | <scp>MET</scp> inhibition overcomes radiation resistance of glioblastoma stemâ€like cells. EMBO Molecular Medicine, 2016, 8, 550-568. | 6.9 | 74 |
| 25 | Dual Constant Domainâ€Fab: A novel strategy to improve halfâ€life and potency of a Met therapeutic antibody. Molecular Oncology, 2016, 10, 938-948. | 4.6 | 11 |
| 26 | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 738-746. | 10.7 | 778 |
| 27 | Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncology, The, 2016, 17, 1386-1395. | 10.7 | 357 |
| 28 | Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals. BMC Biology, 2016, 14, 5. | 3.8 | 20 |
| 29 | Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. Journal of Molecular and Cellular Cardiology, 2016, 93, 84-97. | 1.9 | 12 |
| 30 | C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. Oncotarget, 2016, 7, 45525-45537. | 1.8 | 24 |
| 31 | Inhibition of ligandâ€independent constitutive activation of the Met oncogenic receptor by the engineered chemicallyâ€modified antibody DN30. Molecular Oncology, 2015, 9, 1760-1772. | 4.6 | 18 |
| 32 | IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Science Translational Medicine, 2015, 7, 272ra12. | 12.4 | 100 |
| 33 | Targeting the oncogenic Met receptor by antibodies and gene therapy. Oncogene, 2015, 34, 1883-1889. | 5.9 | 35 |
| 34 | TNFâ€Î± promotes invasive growth through the MET signaling pathway. Molecular Oncology, 2015, 9, 377-388. | 4.6 | 40 |
| 35 | Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget, 2015, 6, 5182-5194. | 1.8 | 72 |
| 36 | Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy. Cell Death and Disease, 2014, 5, e1185-e1185. | 6.3 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. Current Opinion in Cell Biology, 2014, 31, 98-105. | 5.4 | 35 |
| 38 | Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs. Cancer Research, 2014, 74, 6598-6609. | 0.9 | 59 |
| 39 | MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. British Journal of Haematology, 2014, 164, 841-850. | 2.5 | 20 |
| 40 | An â€˜inâ€cell trialâ€™ to assess the efficacy of a monovalent antiâ€MET antibody as monotherapy and in association with standard cytotoxics. Molecular Oncology, 2014, 8, 378-388. | 4.6 | 10 |
| 41 | Increase of <i>MET</i> gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. Molecular Oncology, 2014, 8, 1561-1574. | 4.6 | 15 |
| 42 | The ROR1 pseudokinase diversifies signaling outputs in METâ€addicted cancer cells. International Journal of Cancer, 2014, 135, 2305-2316. | 5.1 | 39 |
| 43 | MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors. Cancer Research, 2014, 74, 1857-1869. | 0.9 | 120 |
| 44 | Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. Journal of Molecular Medicine, 2014, 92, 65-76. | 3.9 | 9 |
| 45 | MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells. Cancer Research, 2014, 74, 3647-3651. | 0.9 | 30 |
| 46 | The <i>MET</i> Oncogene in Glioblastoma Stem Cells: Implications as a Diagnostic Marker and a Therapeutic Target. Cancer Research, 2013, 73, 3193-3199. | 0.9 | 56 |
| 47 | Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respiratory Medicine,the, 2013, 1, 251-261. | 10.7 | 74 |
| 48 | Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene, 2013, 32, 1428-1440. | 5.9 | 53 |
| 49 | Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 2013, 3, 658-673. | 9.4 | 585 |
| 50 | S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab. Molecular Cancer Therapeutics, 2013, 12, 1749-1762. | 4.1 | 78 |
| 51 | Sema3Eâ€"Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. Journal of Clinical Investigation, 2013, 123, 5411-5411. | 8.2 | 0 |
| 52 | Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas. Clinical Cancer Research, 2012, 18, 2515-2525. | 7.0 | 172 |
| 53 | MiR-1 Downregulation Cooperates with MACC1 in Promoting <i>MET</i> Overexpression in Human Colon Cancer. Clinical Cancer Research, 2012, 18, 737-747. | 7.0 | 116 |
| 54 | The <i>MET</i> Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype. Cancer Research, 2012, 72, 4537-4550. | 0.9 | 120 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. International Journal of Cancer, 2012, 130, 1357-1366. | 5.1 | 21 |
| 56 | Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14240-14245. | 7.1 | 113 |
| 57 | Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer. Journal of the National Cancer Institute, 2011, 103, 645-661. | 6.3 | 300 |
| 58 | Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis. Cancer Research, 2011, 71, 3132-3141. | 0.9 | 119 |
| 59 | A Molecularly Annotated Platform of Patient-Derived Xenografts (â€œXenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523. | 9.4 | 818 |
| 60 | Ron Kinase Transphosphorylation Sustains <i>MET</i> Oncogene Addiction. Cancer Research, 2011, 71, 1945-1955. | 0.9 | 65 |
| 61 | Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clinical and Experimental Metastasis, 2011, 28, 793-802. | 3.3 | 49 |
| 62 | MET mutations in cancers of unknown primary origin (CUPs). Human Mutation, 2011, 32, 44-50. | 2.5 | 61 |
| 63 | Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations. Clinical Cancer Research, 2011, 17, 3146-3156. | 7.0 | 113 |
| 64 | Abstract 3272: A Met receptor docking site peptide fused to cell-penetrating sequences acts as a powerful inhibitor of angiogenesis and vascular tumour growth. , 2011, , . | | 0 |
| 65 | Sema3Eâ€“Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. Journal of Clinical Investigation, 2011, 121, 2945-2945. | 8.2 | 0 |
| 66 | Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. Oncogene, 2010, 29, 5286-5298. | 5.9 | 22 |
| 67 | MET signalling: principles and functions in development, organ regeneration and cancer. Nature Reviews Molecular Cell Biology, 2010, 11, 834-848. | 37.0 | 1,029 |
| 68 | The Tetraspanin CD151 Is Required for Met-dependent Signaling and Tumor Cell Growth. Journal of Biological Chemistry, 2010, 285, 38756-38764. | 3.4 | 46 |
| 69 | Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody. Journal of Biological Chemistry, 2010, 285, 36149-36157. | 3.4 | 73 |
| 70 | <i>MET</i> and <i>KRAS</i> Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors. Cancer Research, 2010, 70, 7580-7590. | 0.9 | 164 |
| 71 | Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors. Clinical Cancer Research, 2010, 16, 3933-3943. | 7.0 | 39 |
| 72 | A Disintegrin and Metalloproteinase-10 (ADAM-10) Mediates DN30 Antibody-induced Shedding of the Met Surface Receptor. Journal of Biological Chemistry, 2010, 285, 26335-26340. | 3.4 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Molecular Cancer, 2010, 9, 121. | 19.2 | 95 |
| 74 | Targeting the MET oncogene in cancer and metastases. Expert Opinion on Investigational Drugs, 2010, 19, 1381-1394. | 4.1 | 45 |
| 75 | The Met oncogene and basal-like breast cancer: another culprit to watch out for?. Breast Cancer Research, 2010, 12, 208. | 5.0 | 68 |
| 76 | Sema3Eâ€"Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. Journal of Clinical Investigation, 2010, 120, 2684-2698. | 8.2 | 157 |
| 77 | The Fathers of Italian Histology. European Journal of Histochemistry, 2009, 51, 1. | 1.5 | 5 |
| 78 | The Slit/Robo System Suppresses Hepatocyte Growth Factor-dependent Invasion and Morphogenesis. Molecular Biology of the Cell, 2009, 20, 642-657. | 2.1 | 53 |
| 79 | Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction. Science Signaling, 2009, 2, ra80. | 3.6 | 84 |
| 80 | Growth factor receptors and class 1 oncogenes in cancer. Animal Genetics, 2009, 20, 348-350. | 1.7 | 0 |
| 81 | Molecular profiling of the Ã¢Â€ÂœplexinomeÃ¢Â€Â•in melanoma and pancreatic cancer. Human Mutation, 2009, 30, 1167-1174. | 2.5 | 40 |
| 82 | Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene, 2009, 28, 1421-1431. | 5.9 | 81 |
| 83 | Genetic Link Between Cancer and Thrombosis. Journal of Clinical Oncology, 2009, 27, 4827-4833. | 1.6 | 63 |
| 84 | A Correction to the Research Article Titled: "Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction" by A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, J. A. Hickman, P. M. Comoglio, L. Trusolino. Science Signaling, 2009, 2, er11. | 3.6 | 23 |
| 85 | Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. Journal of Clinical Investigation, 2009, 119, 865-875. | 8.2 | 59 |
| 86 | The Met tyrosine kinase receptor in development and cancer. Cancer and Metastasis Reviews, 2008, 27, 85-94. | 5.9 | 303 |
| 87 | Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1857-1867. | 6.4 | 90 |
| 88 | Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology, 2008, 47, 2010-2025. | 7.3 | 15 |
| 89 | Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene, 2008, 27, 684-693. | 5.9 | 126 |
| 90 | Met-driven invasive growth involves transcriptional regulation of Arhgap12. Oncogene, 2008, 27, 5590-5598. | 5.9 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Reviews Drug Discovery, 2008, 7, 504-516. | 46.4 | 737 |
| 92 | Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. Journal of Experimental Medicine, 2008, 205, 1673-1685. | 8.5 | 233 |
| 93 | â€œActiveâ€•Cancer Immunotherapy by Anti-Met Antibody Gene Transfer. Cancer Research, 2008, 68, 9176-9183. | 0.9 | 36 |
| 94 | A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met. Journal of Biological Chemistry, 2008, 283, 21267-21277. | 3.4 | 107 |
| 95 | The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. Journal of Experimental Medicine, 2008, 205, 1155-1171. | 8.5 | 87 |
| 96 | MicroRNAs Impair MET-Mediated Invasive Growth. Cancer Research, 2008, 68, 10128-10136. | 0.9 | 168 |
| 97 | Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of Oncology, 2008, 19, 1605-1612. | 1.2 | 81 |
| 98 | Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis. PLoS ONE, 2008, 3, e3223. | 2.5 | 36 |
| 99 | Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11412-11417. | 7.1 | 38 |
| 100 | The MET receptor tyrosine kinase in invasion and metastasis. Journal of Cellular Physiology, 2007, 213, 316-325. | 4.1 | 230 |
| 101 | Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis. BMC Developmental Biology, 2007, 7, 55. | 2.1 | 69 |
| 102 | A positive feedback loop between hepatocyte growth factor receptor and Î²-catenin sustains colorectal cancer cell invasive growth. Oncogene, 2007, 26, 1078-1087. | 5.9 | 103 |
| 103 | Oncogenes, Cancer and Hemostasis. , 2007, , 1-15. | | 1 |
| 104 | Scatter Factors in Tumor Progression. , 2006, , 111-142. | | 0 |
| 105 | Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nature Reviews Cancer, 2006, 6, 637-645. | 28.4 | 492 |
| 106 | p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. International Journal of Cancer, 2006, 118, 2981-2990. | 5.1 | 38 |
| 107 | Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5090-5095. | 7.1 | 147 |
| 108 | MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas. Cancer Research, 2006, 66, 4750-4757. | 0.9 | 123 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | The Met pathway: master switch and drug target in cancer progression. FASEB Journal, 2006, 20, 1611-1621. | 0.5 | 117 |
| 110 | Î²4 integrin activates a Shp2â€"Src signaling pathway that sustains HGF-induced anchorage-independent growth. Journal of Cell Biology, 2006, 175, 993-1003. | 5.2 | 114 |
| 111 | Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood, 2005, 105, 4321-4329. | 1.4 | 226 |
| 112 | Cancer: the matrix is now in control. Nature Medicine, 2005, 11, 1156-1158. | 30.7 | 85 |
| 113 | TGFÎ± expression impairs Trastuzumab-induced HER2 downregulation. Oncogene, 2005, 24, 3002-3010. | 5.9 | 113 |
| 114 | The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature, 2005, 434, 396-400. | 27.8 | 245 |
| 115 | Î²4 Integrin Is a Transforming Molecule that Unleashes Met Tyrosine Kinase Tumorigenesis. Cancer Research, 2005, 65, 10674-10679. | 0.9 | 70 |
| 116 | A Functional Role for Hemostasis in Early Cancer Development: Figure 1.. Cancer Research, 2005, 65, 8579-8582. | 0.9 | 39 |
| 117 | Proteolytic Processing Converts the Repelling Signal Sema3E into an Inducer of Invasive Growth and Lung Metastasis. Cancer Research, 2005, 65, 6167-6177. | 0.9 | 101 |
| 118 | Negative Feedback Regulation of Met-Dependent Invasive Growth by Notch. Molecular and Cellular Biology, 2005, 25, 3982-3996. | 2.3 | 51 |
| 119 | p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. Journal of Cell Science, 2005, 118, 4689-4700. | 2.0 | 90 |
| 120 | Cell Motility Is Controlled by SF2/ASF through Alternative Splicing of the Ron Protooncogene. Molecular Cell, 2005, 20, 881-890. | 9.7 | 339 |
| 121 | Cancer therapy: can the challenge be MET?. Trends in Molecular Medicine, 2005, 11, 284-292. | 6.7 | 218 |
| 122 | Invasive growth: a genetic program. International Journal of Developmental Biology, 2004, 48, 451-456. | 0.6 | 35 |
| 123 | Hepatocyte Growth Factor/Scatter Factor Receptor. , 2004, , 367-371. | | 0 |
| 124 | Hepatocyte Growth Factor Sensitizes Human Ovarian Carcinoma Cell Lines to Paclitaxel and Cisplatin. Cancer Research, 2004, 64, 1744-1750. | 0.9 | 47 |
| 125 | Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell-Cell Adhesion Through E-Cadherin Transcriptional Repression. Cancer Research, 2004, 64, 5154-5161. | 0.9 | 96 |
| 126 | Reactive Oxygen Species Mediate Met Receptor Transactivation by G Protein-coupled Receptors and the Epidermal Growth Factor Receptor in Human Carcinoma Cells. Journal of Biological Chemistry, 2004, 279, 28970-28978. | 3.4 | 108 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Invasive growth: A two-way street for semaphorin signalling. Nature Cell Biology, 2004, 6, 1155-1157. | 10.3 | 18 |
| 128 | To move or not to move?. EMBO Reports, 2004, 5, 356-361. | 4.5 | 150 |
| 129 | Plexinâ€B3 is a functional receptor for semaphorin 5A. EMBO Reports, 2004, 5, 710-714. | 4.5 | 132 |
| 130 | Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene, 2004, 23, 5131-5137. | 5.9 | 164 |
| 131 | Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 2004, 6, 61-73. | 16.8 | 282 |
| 132 | An uncleavable form of proâ€“scatter factor suppresses tumor growth and dissemination in mice. Journal of Clinical Investigation, 2004, 114, 1418-1432. | 8.2 | 85 |
| 133 | Interactions between growth factor receptors and adhesion molecules: breaking the rules. Current Opinion in Cell Biology, 2003, 15, 565-571. | 5.4 | 240 |
| 134 | Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003, 3, 347-361. | 16.8 | 1,244 |
| 135 | Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends in Biochemical Sciences, 2003, 28, 527-533. | 7.5 | 153 |
| 136 | Hepatocyte growth factor and its receptor are required for malaria infection. Nature Medicine, 2003, 9, 1363-1369. | 30.7 | 133 |
| 137 | The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Experimental Cell Research, 2003, 288, 382-389. | 2.6 | 104 |
| 138 | Mutations in the met Oncogene Unveil a â€œDual Switchâ€•Mechanism Controlling Tyrosine Kinase Activity. Journal of Biological Chemistry, 2003, 278, 29352-29358. | 3.4 | 41 |
| 139 | Functional Regulation of Semaphorin Receptors by Proprotein Convertases. Journal of Biological Chemistry, 2003, 278, 10094-10101. | 3.4 | 67 |
| 140 | A differentiation switch for genetically modified hepatocytes. FASEB Journal, 2002, 16, 1-18. | 0.5 | 15 |
| 141 | Feline STK gene expression in mammary carcinomas. Oncogene, 2002, 21, 1785-1790. | 5.9 | 28 |
| 142 | The endophilinâ€“CIN85â€“Cbl complex mediates ligand-dependent downregulation of c-Met. Nature, 2002, 416, 187-190. | 27.8 | 424 |
| 143 | An HGFâ€“MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nature Biotechnology, 2002, 20, 488-495. | 17.5 | 22 |
| 144 | The Semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biology, 2002, 4, 720-724. | 10.3 | 391 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Reviews Cancer, 2002, 2, 289-300. | 28.4 | 707 |
| 146 | Series Introduction: Invasive growth: from development to metastasis. Journal of Clinical Investigation, 2002, 109, 857-862. | 8.2 | 154 |
| 147 | Series Introduction: Invasive growth: from development to metastasis. Journal of Clinical Investigation, 2002, 109, 857-862. | 8.2 | 95 |
| 148 | Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Research, 2002, 62, 7025-30. | 0.9 | 92 |
| 149 | The Transmembrane Protein Off-Track Associates with Plexins and Functions Downstream of Semaphorin Signaling during Axon Guidance. Neuron, 2001, 32, 53-62. | 8.1 | 153 |
| 150 | A Signaling Adapter Function for Î±6Î²4 Integrin in the Control of HGF-Dependent Invasive Growth. Cell, 2001, 107, 643-654. | 28.9 | 412 |
| 151 | Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene. Current Drug Targets, 2001, 2, 41-55. | 2.1 | 56 |
| 152 | Scatter factors and invasive growth. Seminars in Cancer Biology, 2001, 11, 153-165. | 9.6 | 112 |
| 153 | A gene trap vector system for identifying transcriptionally responsive genes. Nature Biotechnology, 2001, 19, 579-582. | 17.5 | 69 |
| 154 | Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling. Oncogene, 2001, 20, 156-166. | 5.9 | 41 |
| 155 | Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness. Oncogene, 2001, 20, 5493-5502. | 5.9 | 6 |
| 156 | Pathway specificity for Met signalling. Nature Cell Biology, 2001, 3, E161-E162. | 10.3 | 85 |
| 157 | Macrophage Stimulating Protein Is a Novel Neurotrophic Factor. Molecular Biology of the Cell, 2001, 12, 1341-1352. | 2.1 | 26 |
| 158 | Apoptosis Enhancement by the HIV-1 Nef Protein. Journal of Immunology, 2001, 166, 81-88. | 0.8 | 91 |
| 159 | Hepatocyte Growth Factor Is a Regulator of Monocyte-Macrophage Function. Journal of Immunology, 2001, 166, 1241-1247. | 0.8 | 129 |
| 160 | Ligand-regulated Binding of FAP68 to the Hepatocyte Growth Factor Receptor. Journal of Biological Chemistry, 2001, 276, 46632-46638. | 3.4 | 32 |
| 161 | HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB Journal, 2000, 14, 1629-1640. | 0.5 | 88 |
| 162 | Staging of head and neck squamous cell carcinoma using theMET oncogene product as marker of tumor cells in lymph node metastases. International Journal of Cancer, 2000, 89, 286-292. | 5.1 | 59 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Sustained recruitment of phospholipase C-Î³ to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene, 2000, 19, 1509-1518. | 5.9 | 154 |
| 164 | Signalling by semaphorin receptors: cell guidance and beyond. Trends in Cell Biology, 2000, 10, 377-383. | 7.9 | 329 |
| 165 | Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. Endocrine Pathology, 2000, 11, 19-30. | 9.0 | 72 |
| 166 | HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB Journal, 2000, 14, 1629-1640. | 0.5 | 90 |
| 167 | Plexins, Semaphorins, and Scatter Factor Receptors: A Common Root for Cell Guidance Signals?. IUBMB Life, 1999, 48, 477-482. | 3.4 | 30 |
| 168 | A Peptide Representing the Carboxyl-terminal Tail of the Met Receptor Inhibits Kinase Activity and Invasive Growth. Journal of Biological Chemistry, 1999, 274, 29274-29281. | 3.4 | 59 |
| 169 | Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene, 1999, 18, 1139-1146. | 5.9 | 77 |
| 170 | Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. Oncogene, 1999, 18, 4275-4281. | 5.9 | 58 |
| 171 | Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene, 1999, 18, 5221-5231. | 5.9 | 139 |
| 172 | Plexins, Semaphorins, and Scatter Factor Receptors: A Common Root for Cell Guidance Signals?. IUBMB Life, 1999, 48, 477-482. | 3.4 | 40 |
| 173 | Novel mutation in the ATP-binding site of theMET oncogene tyrosine kinase in a HPRCC family. , 1999, 82, 640-643. | | 82 |
| 174 | Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid. , 1999, 189, 570-575. | | 33 |
| 175 | HGF: a multifunctional growth factor controlling cell scattering. International Journal of Biochemistry and Cell Biology, 1999, 31, 1357-1362. | 2.8 | 141 |
| 176 | Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates. Cell, 1999, 99, 71-80. | 28.9 | 1,029 |
| 177 | Unified Nomenclature for the Semaphorins/Collapsins. Cell, 1999, 97, 551-552. | 28.9 | 405 |
| 178 | Plasminogen-Related Growth Factor and Semaphorin Receptors: A Gene Superfamily Controlling Invasive Growth. Experimental Cell Research, 1999, 253, 88-99. | 2.6 | 61 |
| 179 | C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells. Clinical and Experimental Metastasis, 1998, 16, 253-265. | 3.3 | 18 |
| 180 | Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 1998, 391, 285-288. | 27.8 | 485 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Overexpression of the RON gene in human breast carcinoma. Oncogene, 1998, 16, 2927-2933. | 5.9 | 190 |
| 182 | Expression ofMet protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. , 1998, 186, 287-291. | | 41 |
| 183 | Plexin A Is a Neuronal Semaphorin Receptor that Controls Axon Guidance. Cell, 1998, 95, 903-916. | 28.9 | 424 |
| 184 | Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14379-14383. | 7.1 | 96 |
| 185 | Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. Biochemical Journal, 1998, 336, 235-239. | 3.7 | 32 |
| 186 | Interactions between scatter factors and their receptors: hints for therapeutic applications. FASEB Journal, 1998, 12, 1267-1280. | 0.5 | 77 |
| 187 | Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases<sup>1</sup>. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2322-2328. | 3.6 | 64 |
| 188 | Ezrin Is an Effector of Hepatocyte Growth Factorâ€"mediated Migration and Morphogenesis in Epithelial Cells. Journal of Cell Biology, 1997, 138, 423-434. | 5.2 | 290 |
| 189 | A Natural Hepatocyte Growth Factor/Scatter Factor Autocrine Loop in Myoblast Cells and the Effect of the Constitutive Met Kinase Activation on Myogenic Differentiation. Journal of Cell Biology, 1997, 137, 1057-1068. | 5.2 | 165 |
| 190 | Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. Cytokine and Growth Factor Reviews, 1997, 8, 129-142. | 7.2 | 102 |
| 191 | A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 13868-13872. | 7.1 | 90 |
| 192 | Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. Oncogene, 1997, 14, 705-711. | 5.9 | 51 |
| 193 | Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene, 1997, 14, 2417-2423. | 5.9 | 144 |
| 194 | Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene, 1997, 15, 3103-3111. | 5.9 | 122 |
| 195 | â€œInvasive-growthâ€•signaling by the Met/HGF receptor. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1333, M41-M51. | 7.4 | 30 |
| 196 | Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO Journal, 1997, 16, 495-503. | 7.8 | 156 |
| 197 | Control of invasive growth by the HGF receptor family. Journal of Cellular Physiology, 1997, 173, 183-186. | 4.1 | 35 |
| 198 | Scatter Factor Receptors are Key Players in a Unique Multistep Program Leading to Invasive Growth. Novartis Foundation Symposium, 1997, 212, 133-154. | 1.1 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2322-2328. | 3.6 | 63 |
| 200 | Uncoupling of Grb2 from the Met Receptor In Vivo Reveals Complex Roles in Muscle Development. Cell, 1996, 87, 531-542. | 28.9 | 306 |
| 201 | A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 674-678. | 7.1 | 169 |
| 202 | The hepatocyte growth factor receptor (MET): An unconventional transducer of mitogenic and motogenic signals. Growth Factors and Cytokines in Health and Disease, 1996, 1, 465-490. | 0.2 | 1 |
| 203 | Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7644-7648. | 7.1 | 202 |
| 204 | EXPRESSION OFMet PROTEIN IN THYROID TUMOURS. , 1996, 180, 266-270. | | 79 |
| 205 | Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. , 1996, 65, 168-172. | | 36 |
| 206 | Overexpression of the met/HGF receptor in renal cell carcinomas. , 1996, 69, 212-217. | | 127 |
| 207 | The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes To Cells, 1996, 1, 347-354. | 1.2 | 67 |
| 208 | The HIV-1 Nef Protein Interferes with Phosphatidylinositol 3-Kinase Activation 1. Journal of Biological Chemistry, 1996, 271, 6590-6593. | 3.4 | 55 |
| 209 | Specific Uncoupling of GRB2 from the Met Receptor. Journal of Biological Chemistry, 1996, 271, 14119-14123. | 3.4 | 141 |
| 210 | Control of Invasive Cell Growth by the Met Family Oncogenes. , 1996, , 23-43. | | 0 |
| 211 | Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology, 1995, 21, 1543-1546. | 7.3 | 35 |
| 212 | In Vivo Activation of<i>met</i>Tyrosine Kinase by Heterodimeric Hepatocyte Growth Factor Molecule Promotes Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1857-1865. | 2.4 | 89 |
| 213 | Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction. Journal of Biological Chemistry, 1995, 270, 603-611. | 3.4 | 232 |
| 214 | Overexpression of the C-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. Journal of Endocrinological Investigation, 1995, 18, 134-139. | 3.3 | 63 |
| 215 | Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions*1. Hepatology, 1995, 21, 1543-1546. | 7.3 | 6 |
| 216 | Structure and functions of the HGF receptor (c-Met). , 1995, , 51-70. | | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors.. Journal of Cell Biology, 1994, 127, 1743-1754. | 5.2 | 128 |
| 218 | Overexpression of theMET/HGF receptor in ovarian cancer. International Journal of Cancer, 1994, 58, 658-662. | 5.1 | 208 |
| 219 | A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell, 1994, 77, 261-271. | 28.9 | 980 |
| 220 | Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. Journal of Biotechnology, 1994, 37, 109-122. | 3.8 | 54 |
| 221 | Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissues. Brain Research, 1994, 637, 308-312. | 2.2 | 74 |
| 222 | Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 649-653. | 7.1 | 152 |
| 223 | Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. British Journal of Cancer, 1993, 68, 746-750. | 6.4 | 184 |
| 224 | A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11574-11578. | 7.1 | 219 |
| 225 | Regional mapping of the human hepatocyte growth factor (HGF)-scatter factor gene to chromosome 7q21.1. Genomics, 1992, 13, 912-914. | 2.9 | 26 |
| 226 | Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genetics and Cytogenetics, 1992, 64, 170-173. | 1.0 | 68 |
| 227 | The Receptor for the Hepatocyte Growth Factor-Scatter Factor: Ligand-Dependent and Phosphorylation-Dependent Regulation of Kinase Activity. , 1992, , 301-310. |  | 0 |
| 228 | Constitutively activatedneu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation. Journal of Cellular Biochemistry, 1991, 45, 69-81. | 2.6 | 7 |
| 229 | The receptor encoded by the human Câ€‹<i>MET</i> oncogene is expressed in hepatocytes, epithelial cells and solid tumors. International Journal of Cancer, 1991, 49, 323-328. | 5.1 | 295 |
| 230 | Ligand-Independent Tyrosine Phosphorylation of the Receptor Encoded by thec-neuOncogene. Growth Factors, 1991, 5, 233-242. | 1.7 | 5 |
| 231 | Regulation by EGF is maintained in an overexpressed chimeric EGFR/neureceptor tyrosine kinase. Journal of Cellular Biochemistry, 1990, 42, 123-133. | 2.6 | 12 |
| 232 | Solubilization of the receptor for the neuropeptide gastrin-releasing peptide (bombesin) with functional ligand binding properties. Biochemistry, 1990, 29, 5153-5160. | 2.5 | 25 |
| 233 | Characterization of the detergent solubilized receptor for gastrin-releasing peptide. Peptides, 1990, 11, 737-745. | 2.4 | 3 |
| 234 | Kinetics of tyrosine phosphorylation and internalization of human EGF receptors overexpressed in NIH 3T3 fibroblasts. Experimental Cell Research, 1990, 191, 323-327. | 2.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Lipid characteristics of RSV-transformed Balb/c 3T3 cell lines with different spontaneous metastatic potentials. Lipids, 1989, 24, 685-690. | 1.7 | 21 |
| 236 | Biochemical and immunological properties of the human carcinoma antigen car-5 defined by the monoclonal antibody BD-5. International Journal of Cancer, 1989, 44, 67-74. | 5.1 | 8 |
| 237 | Blocked and not blocked whole-ricin-antibody immunotoxins: Intraperitoneal therapy of human tumour xenografted in nude mice. Cancer Immunology, Immunotherapy, 1989, 29, 185-92. | 4.2 | 10 |
| 238 | Vanadate-treated baby hamster kidney fibroblasts show cytoskeleton and adhesion patterns similar to their rous sarcoma virus-transformed counterparts. Journal of Cellular Biochemistry, 1988, 37, 151-159. | 2.6 | 36 |
| 239 | Evidence for autocrine activation of a tyrosine kinase in a human gastric carcinoma cell line. Journal of Cellular Biochemistry, 1988, 38, 229-236. | 2.6 | 15 |
| 240 | Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines. Cancer Immunology, Immunotherapy, 1988, 27, 233-40. | 4.2 | 17 |
| 241 | A Tyrosine Protein Kinase Activated by Bombesin in Normal Fibroblasts and Small Cell Carcinomas. Annals of the New York Academy of Sciences, 1988, 547, 293-302. | 3.8 | 5 |
| 242 | Effect of the growth conditions on the expression of cell-surface-associated platelet-derived growth factor receptors in mouse fibroblasts. Biochimica Et Biophysica Acta - Molecular Cell Research, 1988, 971, 351-357. | 4.1 | 0 |
| 243 | Effect of the growth conditions on the expression of cell-surface-associated platelet-derived growth factor receptors in mouse fibroblasts. Biochimica Et Biophysica Acta - Bioenergetics, 1988, 971, 351-357. | 1.0 | 2 |
| 244 | The tyrosine kinase associated with the bombesin receptor complex: Evidences for autocrine activation in small cell lung carcinomas. Lung Cancer, 1988, 4, 190-195. | 2.0 | 1 |
| 245 | Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2166-2170. | 7.1 | 37 |
| 246 | Detection of Deregulated Tyrosine-Kinases in Experimental and Human Metastatic Tumors. Advances in Experimental Medicine and Biology, 1988, 233, 303-308. | 1.6 | 0 |
| 247 | Interaction of Fibroblasts, Hemopoietic Cells and Platelets with Extracellular Matrix: Characterization and Role of a Common Cell Surface Glycoprotein. Annals of the New York Academy of Sciences, 1987, 511, 65-76. | 3.8 | 1 |
| 248 | Protein Tyrosine Kinases Associated with Human Malignancies. Annals of the New York Academy of Sciences, 1987, 511, 256-261. | 3.8 | 14 |
| 249 | Expression of the monoclonal antibody-defined CAR-3 epitope on neoplastic and preneoplastic lesions of the colon mucosa. European Journal of Cancer & Clinical Oncology, 1987, 23, 923-932. | 0.7 | 5 |
| 250 | Proteins phosphorylated on tyrosine as markers of human tumor cell lines. International Journal of Cancer, 1987, 39, 482-487. | 5.1 | 18 |
| 251 | PDGF-induced receptor phosphorylation and phosphoinositide hydrolysis are unaffected by protein kinase C activation in mouse Swiss 3T3 and human skin fibroblasts. Biochemical and Biophysical Research Communications, 1986, 137, 343-350. | 2.1 | 48 |
| 252 | Bombesin stimulation of c-fos and c-myc gene expression in cultures of Swiss 3T3 cells. Experimental Cell Research, 1986, 167, 276-280. | 2.6 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | A 135000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion. Experimental Cell Research, 1986, 163, 47-62. | 2.6 | 75 |
| 254 | In vivo phosphorylation and dephosphorylation of the platelet-derived growth factor receptor studied by immunoblot analysis with phosphotyrosine antibodies. Biochimica Et Biophysica Acta - General Subjects, 1986, 881, 54-61. | 2.4 | 49 |
| 255 | Protein phosphorylation at tyrosine residues INv-abl transformed mouse lymphocytes and fibroblasts. International Journal of Cancer, 1986, 37, 623-628. | 5.1 | 12 |
| 256 | Immunological detection of proteins phosphorylated at tyrosine in cells stimulated by growth factors or transformed by retroviral-oncogene-coded tyrosine kinases. FEBS Journal, 1986, 158, 383-391. | 0.2 | 36 |
| 257 | Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. Experimental Cell Research, 1985, 159, 141-157. | 2.6 | 388 |
| 258 | Organization of cytoskeleton and fibronectin matrix in rous sarcoma virus (RSV)-transformed fibroblast lines with different metastatic potential. European Journal of Cancer & Clinical Oncology, 1985, 21, 85-96. | 0.7 | 9 |
| 259 | Role of heterochromatin variation in the instability of a marker chromosome during tumor progression. Cancer Genetics and Cytogenetics, 1985, 15, 283-291. | 1.0 | 14 |
| 260 | Phosphoinositides are not phosphorylated by the very active tyrosine protein kinase from the murine lymphoma LSTRA. Biochemical and Biophysical Research Communications, 1985, 132, 481-489. | 2.1 | 5 |
| 261 | Cleavage of a 135 kD cell surface glycoprotein correlates with loss of fibroblast adhesion to fibronectin. Experimental Cell Research, 1985, 156, 182-190. | 2.6 | 100 |
| 262 | Monoclonal Antibodies to the Collagen Binding Domain of Human Plasma Fibronectin. Pathobiology, 1984, 52, 225-236. | 3.8 | 4 |
| 263 | Identification of a 58,000 Daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line. Biochemical and Biophysical Research Communications, 1984, 122, 563-570. | 2.1 | 26 |
| 264 | Immunofluorescence localization of phosphotyrosine containing proteins in RSV-transformed mouse fibroblasts*1. Experimental Cell Research, 1984, 154, 112-124. | 2.6 | 27 |
| 265 | Metastatic clones selected from an RSV-induced mouse sarcoma share a common marker chromosome. International Journal of Cancer, 1983, 31, 455-461. | 5.1 | 19 |
| 266 | Characterization of T lymphocytes mediatingin vivo protection against RSV-induced murine sarcomas. International Journal of Cancer, 1983, 31, 757-764. | 5.1 | 11 |
| 267 | Dissection of the antigenic determinants expressed on the cell surface of rsv-transformed fibroblasts by monoclonal antibodies. International Journal of Cancer, 1982, 29, 477-481. | 5.1 | 6 |
| 268 | Mouse fibroblasts transformed by rous sarcoma virus express a virus-specific non-virion transplantation antigen. International Journal of Cancer, 1981, 27, 797-805. | 5.1 | 11 |
| 269 | Identification and partial characterization of five major membrane glycoproteins of BHK fibroblasts. Journal of Membrane Biology, 1980, 53, 55-61. | 2.1 | 13 |
| 270 | Interaction between cellular and viral genes in the expression of the RSV-induced transformation-specific cell-surface antigen VCSA. International Journal of Cancer, 1980, 25, 355-362. | 5.1 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Cell surface changes during muscle differentiation in vitro: A study with the probe 2,4,6-trinitrobenzene sulphonate. Cell Differentiation, 1979, 8, 1-9. | 0.4 | 6 |
| 272 | A virus-induced non-virion antigen specific for transformation at the surface of RSV-transformed fibroblasts. Nature, 1978, 273, 381-383. | 27.8 | 12 |
| 273 | Tumor-specific and tumor-associated membrane antigens of rous sarcoma virus transformed hamster fibroblasts. International Journal of Cancer, 1978, 22, 55-62. | 5.1 | 7 |
| 274 | Immunochemical purification of probe-labeled plasma membrane proteins: An approach to the molecular anatomy of the cell surface. Journal of Supramolecular Structure, 1978, 8, 39-49. | 2.3 | 6 |
| 275 | Plasma membrane proteins exposed on the outer surface of control and Rous sarcoma virus-transformed hamster fibroblasts. Experimental Cell Research, 1977, 110, 143-152. | 2.6 | 8 |
| 276 | A solid-state competitive binding radioimmunoassay for measurement of antigens solubilized from membranes. Journal of Immunological Methods, 1976, 9, 267-272. | 1.4 | 17 |
| 277 | Binding of serum polypeptides to the plasma membrane outer surface. FEBS Letters, 1976, 67, 364-367. | 2.8 | 14 |
| 278 | Involvement of sialic acids in the immunological specificity of plasma membrane glycoproteins. Immunochemistry, 1976, 13, 97-102. | 1.2 | 4 |
| 279 | Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes. British Journal of Cancer, 1976, 34, 233-238. | 6.4 | 7 |
| 280 | Studies on the outer surface of normal and RSV-transformed BHK fibroblast plasma membrane. Experimental Cell Research, 1975, 93, 402-410. | 2.6 | 16 |
| 281 | Antigenic and immunogenic properties of membrane proteins solubilized by sodium desoxycholate, papain digestion or high ionic strength. Immunochemistry, 1975, 12, 9-17. | 1.2 | 28 |
| 282 | Neuraminidase sensitive antigenic determinants of plasma cell tumor membrane glycoproteins. FEBS Letters, 1975, 51, 351-354. | 2.8 | 8 |
| 283 | A comparative study of SV40-transformed fibroblast plasma membrane proteins labelled by enzymatic iodination or with trinitrobenzene sulfonate. FEBS Letters, 1974, 47, 107-112. | 2.8 | 18 |
| 284 | Effect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts. British Journal of Cancer, 1974, 30, 365-369. | 6.4 | 8 |
| 285 | Plasma-cell and tumor-associated membrane antigens of mouse plasmacytoma MOPC-315 and MOPC-460. International Journal of Cancer, 1973, 12, 613-625. | 5.1 | 6 |
| 286 | Growth of Syngeneic Tumours in Unimmunized Newborn and Adult Hosts. British Journal of Cancer, 1973, 27, 120-127. | 6.4 | 15 |
| 287 | Affinity chromatography purification of erythrocyte membrane proteins after selective labeling with trinitrobenzene sodium sulfonate. Biochimica Et Biophysica Acta - Biomembranes, 1973, 311, 214-221. | 2.6 | 27 |
| 288 | Two dimensional distribution of concanavalin-A receptor molecules on fibroblast and lymphocyte plasma membranes. FEBS Letters, 1972, 27, 256-258. | 2.8 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Antigen-dependent mast cell differentiation in vitro. Experimental Cell Research, 1972, 72, 404-408. | 2.6 | 1 |
| 290 | Morphological and biochemical changes of rat prostate organ cultures and their reaction to prostate extracts. Life Sciences, 1971, 10, 325-331. | 4.3 | 0 |
| 291 | Multinucleated giant cells in organ cultures of spleen. Experientia, 1969, 25, 61-62. | 1.2 | 1 |